Inicio
Resultado de la búsqueda
9 búsqueda de la palabra clave 'Pituitary carcinoma'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Título : Biomarkers of pituitary carcinomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2016 Títulos uniformes : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : Angiogenesis Galectin-3 HIF-1 H-ras Ki-67 microRNA P27/KIP1 P53 pituitary carcinoma telomerase Resumen : Pituitary carcinoma is a rare tumor originating from adenohypophyseal cells. Currently, diverse pathogenetic mechanisms, i.e. de novo versus malignant transformation from pituitary adenoma, remain obscure and require further investigation. During the last two decades, scientific research added new horizons not only in regards to general tumor concepts but also in next generation biomarker armamentarium that sheds light on alternate pathways in carcinogenesis. Areas covered: In this review, the impact of apoptotic and proliferative markers, angiogenesis, telomerase activity, H-ras, HIF-1, HER-2/neu, Rb gene, and microRNAs in pathogenetic mechanisms of pituitary carcinomas were revised. Expert commentary: It is becoming increasingly important for the need of standardization of new biomarkers but also for better comprehension of the diverse pathways in tumorigenesis. This can only be accomplished by tapping into the continuously expanding spectrum of new biomarkers. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Antonio Di Ieva, Michael D Cusimano, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2016 May;11(3):253-261. DOI (Digital Object Identifier) : 10.1080/17446651.2016.1179110 PMID : 30058931 En línea : https://www.tandfonline.com/doi/abs/10.1080/17446651.2016.1179110 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4611 Biomarkers of pituitary carcinomas [documento electrónico] / Luis Vicente Syro Moreno, . - 2016.
Obra : Expert Review of Endocrinology and Metabolism
Idioma : Inglés (eng)
Palabras clave : Angiogenesis Galectin-3 HIF-1 H-ras Ki-67 microRNA P27/KIP1 P53 pituitary carcinoma telomerase Resumen : Pituitary carcinoma is a rare tumor originating from adenohypophyseal cells. Currently, diverse pathogenetic mechanisms, i.e. de novo versus malignant transformation from pituitary adenoma, remain obscure and require further investigation. During the last two decades, scientific research added new horizons not only in regards to general tumor concepts but also in next generation biomarker armamentarium that sheds light on alternate pathways in carcinogenesis. Areas covered: In this review, the impact of apoptotic and proliferative markers, angiogenesis, telomerase activity, H-ras, HIF-1, HER-2/neu, Rb gene, and microRNAs in pathogenetic mechanisms of pituitary carcinomas were revised. Expert commentary: It is becoming increasingly important for the need of standardization of new biomarkers but also for better comprehension of the diverse pathways in tumorigenesis. This can only be accomplished by tapping into the continuously expanding spectrum of new biomarkers. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Antonio Di Ieva, Michael D Cusimano, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2016 May;11(3):253-261. DOI (Digital Object Identifier) : 10.1080/17446651.2016.1179110 PMID : 30058931 En línea : https://www.tandfonline.com/doi/abs/10.1080/17446651.2016.1179110 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4611 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001109 AC-2016-090 Archivo digital Producción Científica Artículos científicos Disponible
Título : Crooke's cell tumors of the pituitary Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, ; Julian F. Montoya, Fecha de publicación : 2015 Títulos uniformes : Neurosurgery Idioma : Inglés (eng) Palabras clave : Adrenocorticotropic hormone producing pituitary tumor aggressive pituitary adenoma crooke's cell Hyalinization pituitary adenoma pituitary carcinoma Resumen : Crooke's cell adenomas are a rare type of pituitary neoplasm. They produce adrenocorticotropic hormone causing Cushing's disease or may be endocrinologically silent. These tumors are usually invasive, may exhibit aggressive clinical behavior, and often recur with a low success of cure after reoperation and/or radiotherapy. Due to their rarity, they present great difficulties in assessing prognosis, treatment, and clinical management. Neurosurgeons and physicians dealing with pituitary adenomas diagnosed as Crooke's cell adenomas have to be aware of their potential clinical aggressiveness to plan strict follow-up of patients and eventual multimodality treatment. We review here the published cases of Crooke's cell tumors, as well as the clinical and histopathological characteristics of these unusual neoplasms. Mención de responsabilidad : Antonio Di Ieva, Jennilee M Davidson, Luis V Syro, Fabio Rotondo, Julian F Montoya, Eva Horvath, Michael D Cusimano, Kalman Kovacs Referencia : Neurosurgery. 2015 May;76(5):616-22. DOI (Digital Object Identifier) : 10.1227/NEU.0000000000000657 PMID : 25635886 En línea : https://academic.oup.com/neurosurgery/article-abstract/76/5/616/2452062?redirect [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3884 Crooke's cell tumors of the pituitary [documento electrónico] / Luis Vicente Syro Moreno, ; Julian F. Montoya, . - 2015.
Obra : Neurosurgery
Idioma : Inglés (eng)
Palabras clave : Adrenocorticotropic hormone producing pituitary tumor aggressive pituitary adenoma crooke's cell Hyalinization pituitary adenoma pituitary carcinoma Resumen : Crooke's cell adenomas are a rare type of pituitary neoplasm. They produce adrenocorticotropic hormone causing Cushing's disease or may be endocrinologically silent. These tumors are usually invasive, may exhibit aggressive clinical behavior, and often recur with a low success of cure after reoperation and/or radiotherapy. Due to their rarity, they present great difficulties in assessing prognosis, treatment, and clinical management. Neurosurgeons and physicians dealing with pituitary adenomas diagnosed as Crooke's cell adenomas have to be aware of their potential clinical aggressiveness to plan strict follow-up of patients and eventual multimodality treatment. We review here the published cases of Crooke's cell tumors, as well as the clinical and histopathological characteristics of these unusual neoplasms. Mención de responsabilidad : Antonio Di Ieva, Jennilee M Davidson, Luis V Syro, Fabio Rotondo, Julian F Montoya, Eva Horvath, Michael D Cusimano, Kalman Kovacs Referencia : Neurosurgery. 2015 May;76(5):616-22. DOI (Digital Object Identifier) : 10.1227/NEU.0000000000000657 PMID : 25635886 En línea : https://academic.oup.com/neurosurgery/article-abstract/76/5/616/2452062?redirect [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3884 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000464 AC-2015-017 Archivo digital Producción Científica Artículos científicos Disponible
Título : Invasive, atypical and aggressive pituitary adenomas and carcinomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2015 Títulos uniformes : Endocrinology and Metabolism Clinics of North America Idioma : Inglés (eng) Palabras clave : Aggressive pituitary adenoma atypical adenoma invasive adenoma non-invasive adenoma pituitary carcinoma diagnosis Resumen : Aggressive pituitary adenomas have a high risk of recurrence, a lack of therapeutic response, and resistance to conventional treatment. So far, no satisfactory biomarkers are available for predicting their behavior. Some specific pituitary adenoma histotypes are more prone to follow an aggressive behavior. Pituitary carcinomas are rare and show cerebrospinal and/or systemic metastasis. They have worse prognosis than aggressive adenomas, and radiation is of limited use in their treatment. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Antonio Di Ieva, Michael D Cusimano, Kalman Kovacs Referencia : Endocrinol Metab Clin North Am. 2015 Mar;44(1):99-104. DOI (Digital Object Identifier) : 10.1016/j.ecl.2014.10.008 PMID : 25732646 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0889-8529(14)00102-9 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3883 Invasive, atypical and aggressive pituitary adenomas and carcinomas [documento electrónico] / Luis Vicente Syro Moreno, . - 2015.
Obra : Endocrinology and Metabolism Clinics of North America
Idioma : Inglés (eng)
Palabras clave : Aggressive pituitary adenoma atypical adenoma invasive adenoma non-invasive adenoma pituitary carcinoma diagnosis Resumen : Aggressive pituitary adenomas have a high risk of recurrence, a lack of therapeutic response, and resistance to conventional treatment. So far, no satisfactory biomarkers are available for predicting their behavior. Some specific pituitary adenoma histotypes are more prone to follow an aggressive behavior. Pituitary carcinomas are rare and show cerebrospinal and/or systemic metastasis. They have worse prognosis than aggressive adenomas, and radiation is of limited use in their treatment. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Antonio Di Ieva, Michael D Cusimano, Kalman Kovacs Referencia : Endocrinol Metab Clin North Am. 2015 Mar;44(1):99-104. DOI (Digital Object Identifier) : 10.1016/j.ecl.2014.10.008 PMID : 25732646 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0889-8529(14)00102-9 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3883 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000463 AC-2015-016 Archivo digital Producción Científica Artículos científicos Disponible
Título : Temozolomide in aggressive pituitary adenomas and carcinomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Clinics (Sao Paulo) Idioma : Inglés (eng) Palabras clave : Pituitary adenoma pituitary carcinoma MGMT temozolomide review Resumen : Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6 -methylguanine- DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6 -methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6 -methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E Fadul, Eva Horvath, Kalman Kovacs Referencia : Clinics. 2012;67(S1):119-23. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)20 PMID : 22584716 En línea : https://www.revistas.usp.br/clinics/article/view/19731 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3606 Temozolomide in aggressive pituitary adenomas and carcinomas [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : Clinics (Sao Paulo)
Idioma : Inglés (eng)
Palabras clave : Pituitary adenoma pituitary carcinoma MGMT temozolomide review Resumen : Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6 -methylguanine- DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6 -methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6 -methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E Fadul, Eva Horvath, Kalman Kovacs Referencia : Clinics. 2012;67(S1):119-23. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)20 PMID : 22584716 En línea : https://www.revistas.usp.br/clinics/article/view/19731 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3606 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000176 AC-2012-016 Archivo digital Producción Científica Artículos científicos Disponible
Título : Treatment of aggressive pituitary adenomas and carcinomas – an overview Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : European Neurological Review Idioma : Inglés (eng) Palabras clave : Pituitary adenoma pituitary carcinoma O6-methylguanine-DNA methyltransferase (MGMT) temozolomide everolimus bevacizumab Resumen : Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumours, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumours and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumours are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs Referencia : European Neurological Review. 2012;7(3):178–80. DOI (Digital Object Identifier) : 10.17925/ENR.2012.07.03.178 En línea : https://touchneurology.com/treatment-of-aggressive-pituitary-adenomas-and-carcin [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3630 Treatment of aggressive pituitary adenomas and carcinomas – an overview [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : European Neurological Review
Idioma : Inglés (eng)
Palabras clave : Pituitary adenoma pituitary carcinoma O6-methylguanine-DNA methyltransferase (MGMT) temozolomide everolimus bevacizumab Resumen : Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumours, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumours and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumours are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs Referencia : European Neurological Review. 2012;7(3):178–80. DOI (Digital Object Identifier) : 10.17925/ENR.2012.07.03.178 En línea : https://touchneurology.com/treatment-of-aggressive-pituitary-adenomas-and-carcin [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3630 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000200 AC-2012-040 Archivo digital Producción Científica Artículos científicos Disponible PermalinkPermalinkPermalinkPermalink
